etoposide - CISMeF

Preferred Label : etoposide;

MeSH definition : A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.;

MeSH synonym : demethyl epipodophyllotoxin ethylidine glucoside; eposide;

CISMeF synonym : pharmacia brand of etoposide; eto cs; Bristol-Myers brand of etoposide; Bristol-Myers squibb brand of etoposide; baxter brand of etoposide; baxter oncology brand of etoposide; bristol myers brand of etoposide; bristol myers squibb brand of etoposide; ferrer brand of etoposide; gry brand of etoposide; lemery brand of etoposide; medac brand of etoposide; novartis brand of etoposide; onkoworks brand of etoposide; pharmachemie brand of etoposide; pierre fabre brand of etoposide; prasfarma brand of etoposide; ribosepharm brand of etoposide; sanfer brand of etoposide; tedec meiji brand of etoposide; teva brand of etoposide; etomedac;

CISMeF acronym : VP16;

DeCS synonym : VP16; V p side Sandoz; V p side-Sandoz;

MeSH hyponym : riboposid; etoposide, (5a alpha)-Isomer; etoposide, (5a alpha,9 alpha)-Isomer; etoposide pierre fabre; celltop; onkoposid; toposar; etoposide, alpha-D-Glucopyranosyl isomer; etoposide, (5S)-Isomer; lastet; exitop; NSC-141540; Eto-GRY; etoposido ferrer farma; etopos; vepesid; VP-16; VP 16-213; Vépéside-Sandoz; eposin; Eto GRY; Etoposide, alpha D Glucopyranosyl Isomer; alpha-D-Glucopyranosyl Isomer Etoposide; NSC 141540; NSC141540; Etoposide Teva; Teva, Etoposide; VP 16 213; VP 16213; VP 16; VP16; Vépéside Sandoz;

MeSH CAS label : Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-;

MeSH Related Number : etoposide, (5a alpha)-Isomer; etoposide, (5a alpha,9 alpha)-Isomer; etoposide, (5S)-Isomer; etoposide, alpha-D-Glucopyranosyl isomer; 100007-53-2 (alpha-D-glucopyranosyl isomer); 33419-42-0 (Etoposide); 89301-95-1 ((5S)-isomer); 96554-38-0 ((5a alpha)-isomer); 96554-41-5 ((5a alpha,9 alpha)-isomer);

Registry Number MeSH : 33419-42-0;

Related CAS MeSH : 96554-38-0 (Etoposide, (5a alpha)-Isomer); 96554-41-5 (Etoposide, (5a alpha,9 alpha)-Isomer); 89301-95-1 (Etoposide, (5S)-Isomer); 100007-53-2 (Etoposide, alpha-D-Glucopyranosyl isomer);

Wikipedia link : https://en.wikipedia.org/wiki/Etoposide;

Codes EINECS : 251-509-1;

Is substance : O;

UNII : 6PLQ3CP4P3;

InChIKey : VJJPUSNTGOMMGY-MRVIYFEKSA-N;

Details

Origin ID

D005047;

UMLS CUI

C0015133;

ATC code(s)
- etoposide [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Etoposide adverse reaction (disorder) [SNOMED CT concept]
- Etoposide poisoning (disorder) [SNOMED CT concept]
- etoposide [Substance BNPC]
Currated CISMeF NLP mapping
- Etoposide [ICD-11 Extension code]
- Etoposide [NCIt concept]
- Etoposide (substance) [SNOMED CT concept]
- etoposide [SNOMED Notion]
Pharmacological action(s)
- antineoplastic agents, phytogenic [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
- topoisomerase II inhibitors [MeSH Descriptor]
Record concept(s)
- Eto-GRY [MeSH concept]
- Etomedac [MeSH concept]
- NSC-141540 [MeSH concept]
- VP 16-213 [MeSH concept]
- VP-16 [MeSH concept]
- Vépéside-Sandoz [MeSH concept]
- celltop [MeSH concept]
- eposin [MeSH concept]
- etopos [MeSH concept]
- etoposide [MeSH concept]
- etoposide pierre fabre [MeSH concept]
- etoposide, (5S)-Isomer [MeSH concept]
- etoposide, (5a alpha)-Isomer [MeSH concept]
- etoposide, (5a alpha,9 alpha)-Isomer [MeSH concept]
- etoposide, alpha-D-Glucopyranosyl isomer [MeSH concept]
- etoposido ferrer farma [MeSH concept]
- exitop [MeSH concept]
- lastet [MeSH concept]
- onkoposid [MeSH concept]
- riboposid [MeSH concept]
- toposar [MeSH concept]
- vepesid [MeSH concept]
Related MeSH Supplementary Concept(s)
- 2'-chloroetoposide [MeSH Supplementary Concept]
- 3',4'-dihydroxyetoposide [MeSH Supplementary Concept]
- 4'-O-demethyl-4-((2''-(dimethylamino)ethyl)amino)-4-desoxypodophyllotoxin [MeSH Supplementary Concept]
- 4'-O-demethyl-4-((3''-(dimethylamino)propyl)amino)-4-desoxypodophyllotoxin [MeSH Supplementary Concept]
- 4'-O-demethyl-4-((4''-(1''-benzylpiperidinyl))amino)-4-desoxypodophyllotoxin [MeSH Supplementary Concept]
- 4'-O-demethyl-4-(4''-(benzimidazol-2''-yl)anilino)-4-desoxypodophyllotoxin [MeSH Supplementary Concept]
- 4'-ester etoposide [MeSH Supplementary Concept]
- A-TRIPLE-V protocol [MeSH Supplementary Concept]
- AB-triple V protocol [MeSH Supplementary Concept]
- ABEP protocol 1 [MeSH Supplementary Concept]
- ABEP protocol 2 [MeSH Supplementary Concept]
- ACE protocol 1 [MeSH Supplementary Concept]
- ACE protocol 2 [MeSH Supplementary Concept]
- ACOP-E protocol [MeSH Supplementary Concept]
- AEP protocol [MeSH Supplementary Concept]
- ALL-85 protocol [MeSH Supplementary Concept]
- AML91 protocol [MeSH Supplementary Concept]
- ANG 1009 [MeSH Supplementary Concept]
- ANLL91 protocol [MeSH Supplementary Concept]
- AOPE protocol [MeSH Supplementary Concept]
- AVI protocol [MeSH Supplementary Concept]
- AVPP protocol [MeSH Supplementary Concept]
- AclBEP protocol [MeSH Supplementary Concept]
- B-8801 protocol [MeSH Supplementary Concept]
- B-triple-V protocol [MeSH Supplementary Concept]
- BACOD-VP16 protocol [MeSH Supplementary Concept]
- BAEC protocol [MeSH Supplementary Concept]
- BAVC protocol [MeSH Supplementary Concept]
- BCHE protocol [MeSH Supplementary Concept]
- BEACOPP protocol [MeSH Supplementary Concept]
- BEAM regimen [MeSH Supplementary Concept]
- BECALM protocol [MeSH Supplementary Concept]
- BEM protocol [MeSH Supplementary Concept]
- BEMOP-CA protocol [MeSH Supplementary Concept]
- BEMP protocol [MeSH Supplementary Concept]
- BEP protocol [MeSH Supplementary Concept]
- BEPV protocol [MeSH Supplementary Concept]
- BF-9 protocol [MeSH Supplementary Concept]
- BMVC protocol [MeSH Supplementary Concept]
- BODIPY-etoposide [MeSH Supplementary Concept]
- BOMES protocol [MeSH Supplementary Concept]
- BOP-CISCA-POMB-ACE regimen [MeSH Supplementary Concept]
- BOVAPEC protocol [MeSH Supplementary Concept]
- BuCEt protocol [MeSH Supplementary Concept]
- CAE-P protocol [MeSH Supplementary Concept]
- CAEVM protocol [MeSH Supplementary Concept]
- CAMBO-VIP protocol [MeSH Supplementary Concept]
- CAMEO protocol [MeSH Supplementary Concept]
- CAPE-PALE protocol [MeSH Supplementary Concept]
- CARE protocol [MeSH Supplementary Concept]
- CAV regimen [MeSH Supplementary Concept]
- CAV-HEM protocol [MeSH Supplementary Concept]
- CAVP protocol [MeSH Supplementary Concept]
- CBV protocol [MeSH Supplementary Concept]
- CCAVP16 protocol [MeSH Supplementary Concept]
- CCE protocol [MeSH Supplementary Concept]
- CE-AVN protocol [MeSH Supplementary Concept]
- CE-CAP protocol [MeSH Supplementary Concept]
- CEA protocol [MeSH Supplementary Concept]
- CEBA combination [MeSH Supplementary Concept]
- CEC protocol [MeSH Supplementary Concept]
- CEE protocol [MeSH Supplementary Concept]
- CEMP protocol [MeSH Supplementary Concept]
- CEO-PE protocol [MeSH Supplementary Concept]
- CEOP-IMVP-Dexa regimen [MeSH Supplementary Concept]
- CEP protocol [MeSH Supplementary Concept]
- CEPP protocol [MeSH Supplementary Concept]
- CEV regimen [MeSH Supplementary Concept]
- CEVAD protocol [MeSH Supplementary Concept]
- CEVD protocol [MeSH Supplementary Concept]
- CEVP protocol [MeSH Supplementary Concept]
- CHASE protocol [MeSH Supplementary Concept]
- CHEP protocol [MeSH Supplementary Concept]
- CHOEP protocol [MeSH Supplementary Concept]
- CHOP-V-MMV protocol [MeSH Supplementary Concept]
- CHOP-VP16 protocol [MeSH Supplementary Concept]
- CMED protocol [MeSH Supplementary Concept]
- CMV regimen [MeSH Supplementary Concept]
- COCE protocol [MeSH Supplementary Concept]
- COMET-A protocol [MeSH Supplementary Concept]
- COMP-VAN protocol [MeSH Supplementary Concept]
- COMPE protocol [MeSH Supplementary Concept]
- COMVP protocol [MeSH Supplementary Concept]
- COPE regimen [MeSH Supplementary Concept]
- COPEP protocol [MeSH Supplementary Concept]
- CPVP protocol [MeSH Supplementary Concept]
- CTEC protocol [MeSH Supplementary Concept]
- CTR III protocol [MeSH Supplementary Concept]
- CVACE protocol [MeSH Supplementary Concept]
- CisEBP protocol [MeSH Supplementary Concept]
- D-CECaT regimen [MeSH Supplementary Concept]
- DAV regimen [MeSH Supplementary Concept]
- DCEP protocol [MeSH Supplementary Concept]
- DCTER protocol [MeSH Supplementary Concept]
- DEB-M protocol [MeSH Supplementary Concept]
- DICE protocol [MeSH Supplementary Concept]
- DIZE protocol [MeSH Supplementary Concept]
- DT PACE regimen [MeSH Supplementary Concept]
- DT-PACE protocol [MeSH Supplementary Concept]
- DVP (cisplatin) [MeSH Supplementary Concept]
- Dexa-BEAM protocol [MeSH Supplementary Concept]
- EAC regimen [MeSH Supplementary Concept]
- EACB protocol [MeSH Supplementary Concept]
- EAP protocol [MeSH Supplementary Concept]
- EAP-II protocol [MeSH Supplementary Concept]
- EC regimen [MeSH Supplementary Concept]
- EC regimen 2 [MeSH Supplementary Concept]
- ECAPP protocol [MeSH Supplementary Concept]
- ECBC protocol [MeSH Supplementary Concept]
- ECHO protocol [MeSH Supplementary Concept]
- EDAP regimen [MeSH Supplementary Concept]
- EEP protocol [MeSH Supplementary Concept]
- EEPFL protocol [MeSH Supplementary Concept]
- EFP protocol [MeSH Supplementary Concept]
- ELETOP protocol [MeSH Supplementary Concept]
- ELF protocol [MeSH Supplementary Concept]
- ELFE regimen [MeSH Supplementary Concept]
- EMA-CO protocol [MeSH Supplementary Concept]
- EMACO protocol [MeSH Supplementary Concept]
- EMLP protocol [MeSH Supplementary Concept]
- ENSG 3C protocol [MeSH Supplementary Concept]
- EORTC GIMEMA AML-10 protocol [MeSH Supplementary Concept]
- EORTC GIMEMA AML-13 protocol [MeSH Supplementary Concept]
- EP-OMB protocol [MeSH Supplementary Concept]
- EPO protocol [MeSH Supplementary Concept]
- EPOCH protocol [MeSH Supplementary Concept]
- EPVP protocol [MeSH Supplementary Concept]
- ESA protocol [MeSH Supplementary Concept]
- ESAP protocol [MeSH Supplementary Concept]
- ESHAP regimen [MeSH Supplementary Concept]
- ESHAP regimen, modified [MeSH Supplementary Concept]
- ETI protocol [MeSH Supplementary Concept]
- EV protocol [MeSH Supplementary Concept]
- EVA regimen [MeSH Supplementary Concept]
- EVAP protocol [MeSH Supplementary Concept]
- EVAP regimen [MeSH Supplementary Concept]
- EVI protocol [MeSH Supplementary Concept]
- EpPt-OMB protocol [MeSH Supplementary Concept]
- FAPEL protocol [MeSH Supplementary Concept]
- FEP protocol [MeSH Supplementary Concept]
- FEPA protocol [MeSH Supplementary Concept]
- FLEP regimen [MeSH Supplementary Concept]
- G-IDEA protocol [MeSH Supplementary Concept]
- GEMIA protocol [MeSH Supplementary Concept]
- GIMEMA ALL 0394 [MeSH Supplementary Concept]
- GL 331 [MeSH Supplementary Concept]
- HD-CEP regimen [MeSH Supplementary Concept]
- HD-CNV protocol [MeSH Supplementary Concept]
- HM 89 protocol [MeSH Supplementary Concept]
- HM 91 protocol [MeSH Supplementary Concept]
- HOPE-Bleo protocol [MeSH Supplementary Concept]
- HR-3 protocol [MeSH Supplementary Concept]
- ICBV regimen [MeSH Supplementary Concept]
- ICE protocol 1 [MeSH Supplementary Concept]
- ICE protocol 2 [MeSH Supplementary Concept]
- ICE protocol 3 [MeSH Supplementary Concept]
- ICE protocol 4 [MeSH Supplementary Concept]
- ICE protocol 5 [MeSH Supplementary Concept]
- ICE protocol 6 [MeSH Supplementary Concept]
- IE protocol [MeSH Supplementary Concept]
- IEV protocol [MeSH Supplementary Concept]
- IEVM protocol [MeSH Supplementary Concept]
- IIVP-16 [MeSH Supplementary Concept]
- IMEP protocol [MeSH Supplementary Concept]
- IMVP-16 protocol [MeSH Supplementary Concept]
- IVAC protocol [MeSH Supplementary Concept]
- IVAD protocol [MeSH Supplementary Concept]
- IVAM regimen [MeSH Supplementary Concept]
- IVEP protocol [MeSH Supplementary Concept]
- JEB protocol [MeSH Supplementary Concept]
- JET protocol [MeSH Supplementary Concept]
- LEAMP protocol [MeSH Supplementary Concept]
- LEMP protocol [MeSH Supplementary Concept]
- LMB89 protocol [MeSH Supplementary Concept]
- LPA97R protocol [MeSH Supplementary Concept]
- LSG15 regimen [MeSH Supplementary Concept]
- MAC-VD protocol [MeSH Supplementary Concept]
- MAE protocol [MeSH Supplementary Concept]
- MAPECO protocol [MeSH Supplementary Concept]
- MAV protocol [MeSH Supplementary Concept]
- MAZE protocol [MeSH Supplementary Concept]
- MB-triple V protocol [MeSH Supplementary Concept]
- MCP 842 regimen [MeSH Supplementary Concept]
- MEA protocol [MeSH Supplementary Concept]
- MEA regimen [MeSH Supplementary Concept]
- MEC regimen [MeSH Supplementary Concept]
- MECA protocol [MeSH Supplementary Concept]
- MECCA protocol [MeSH Supplementary Concept]
- MECHOP-BM protocol [MeSH Supplementary Concept]
- MECP protocol [MeSH Supplementary Concept]
- MEPH protocol [MeSH Supplementary Concept]
- MEPP protocol [MeSH Supplementary Concept]
- MIME protocol [MeSH Supplementary Concept]
- MINE protocol [MeSH Supplementary Concept]
- MINE regimen [MeSH Supplementary Concept]
- MINE-BOP protocol [MeSH Supplementary Concept]
- MINE-ESHAP protocol [MeSH Supplementary Concept]
- MIZE protocol [MeSH Supplementary Concept]
- MLL-93 protocol [MeSH Supplementary Concept]
- MME protocol [MeSH Supplementary Concept]
- MOPLACE protocol [MeSH Supplementary Concept]
- MOPLEC protocol [MeSH Supplementary Concept]
- MPEMi protocol [MeSH Supplementary Concept]
- MPEpiE protocol [MeSH Supplementary Concept]
- MRC AML 10 protocol [MeSH Supplementary Concept]
- MV2 protocol [MeSH Supplementary Concept]
- MVT protocol [MeSH Supplementary Concept]
- NEO-MACOP-B protocol [MeSH Supplementary Concept]
- NOPE protocol [MeSH Supplementary Concept]
- NPF-etoposide [MeSH Supplementary Concept]
- OMEC regimen [MeSH Supplementary Concept]
- OPEC OJEC protocol [MeSH Supplementary Concept]
- OPEC protocol 2 [MeSH Supplementary Concept]
- OPEN protocol [MeSH Supplementary Concept]
- P-DOCE protocol [MeSH Supplementary Concept]
- P-VEBEC protocol [MeSH Supplementary Concept]
- PABlOE protocol [MeSH Supplementary Concept]
- PACE-BOM protocol [MeSH Supplementary Concept]
- PACEBO protocol [MeSH Supplementary Concept]
- PACET protocol [MeSH Supplementary Concept]
- PAE protocol [MeSH Supplementary Concept]
- PAME protocol [MeSH Supplementary Concept]
- PAV-M protocol [MeSH Supplementary Concept]
- PAVE protocol 2 [MeSH Supplementary Concept]
- PAVI protocol [MeSH Supplementary Concept]
- PEA regimen [MeSH Supplementary Concept]
- PEA-M regimen [MeSH Supplementary Concept]
- PEEC protocol [MeSH Supplementary Concept]
- PEEC-M protocol [MeSH Supplementary Concept]
- PEM protocol [MeSH Supplementary Concept]
- PEN protocol [MeSH Supplementary Concept]
- PEP protocol [MeSH Supplementary Concept]
- PET protocol [MeSH Supplementary Concept]
- PETHEMA ALL-3-97 protocol [MeSH Supplementary Concept]
- PEV-B protocol [MeSH Supplementary Concept]
- PMUE protocol [MeSH Supplementary Concept]
- PMUE protocol 2 [MeSH Supplementary Concept]
- PMitCEBO protocol [MeSH Supplementary Concept]
- POEM-Bleo protocol [MeSH Supplementary Concept]
- POG-8498 protocol [MeSH Supplementary Concept]
- POMACE protocol [MeSH Supplementary Concept]
- POMB-ACE protocol [MeSH Supplementary Concept]
- POMB-ACE regimen [MeSH Supplementary Concept]
- POMB-ACE-PAV regimen [MeSH Supplementary Concept]
- PROMACE protocol [MeSH Supplementary Concept]
- PROMACE-CytaBOM protocol [MeSH Supplementary Concept]
- PVP protocol 3 [MeSH Supplementary Concept]
- PVeBV protocol [MeSH Supplementary Concept]
- Pro-MACE-C-MOPP protocol [MeSH Supplementary Concept]
- ProMACE-MOPP protocol [MeSH Supplementary Concept]
- ProMECE-CytaBOM protocol [MeSH Supplementary Concept]
- RIME regimen [MeSH Supplementary Concept]
- T-8801 protocol [MeSH Supplementary Concept]
- TCCSG B-8801 protocol [MeSH Supplementary Concept]
- TEC protocol [MeSH Supplementary Concept]
- TEMP protocol [MeSH Supplementary Concept]
- TOP 53 [MeSH Supplementary Concept]
- TOP 53 glucuronide [MeSH Supplementary Concept]
- V-CAM protocol [MeSH Supplementary Concept]
- VABE protocol [MeSH Supplementary Concept]
- VAC combination [MeSH Supplementary Concept]
- VACIME protocol [MeSH Supplementary Concept]
- VACO-B protocol [MeSH Supplementary Concept]
- VACOP-B protocol [MeSH Supplementary Concept]
- VAD combination [MeSH Supplementary Concept]
- VAE protocol [MeSH Supplementary Concept]
- VAPE protocol [MeSH Supplementary Concept]
- VAPEC-B protocol [MeSH Supplementary Concept]
- VATA protocol [MeSH Supplementary Concept]
- VAV protocol [MeSH Supplementary Concept]
- VBVP protocol [MeSH Supplementary Concept]
- VCAV protocol [MeSH Supplementary Concept]
- VEBEP regimen [MeSH Supplementary Concept]
- VECABOP protocol [MeSH Supplementary Concept]
- VEEP regimen [MeSH Supplementary Concept]
- VEP combination [MeSH Supplementary Concept]
- VEP protocol [MeSH Supplementary Concept]
- VETOPEC protocol [MeSH Supplementary Concept]
- VIC-E protocol [MeSH Supplementary Concept]
- VICED protocol [MeSH Supplementary Concept]
- VICOP-B protocol [MeSH Supplementary Concept]
- VIM-Bleo protocol [MeSH Supplementary Concept]
- VIM-D protocol [MeSH Supplementary Concept]
- VIMB protocol [MeSH Supplementary Concept]
- VIP-B protocol [MeSH Supplementary Concept]
- VIP-E protocol [MeSH Supplementary Concept]
- VIP-VB protocol [MeSH Supplementary Concept]
- VIPP-BM protocol [MeSH Supplementary Concept]
- VMF regimen [MeSH Supplementary Concept]
- VMP regimen [MeSH Supplementary Concept]
- VMV protocol [MeSH Supplementary Concept]
- VNCOP-B protocol [MeSH Supplementary Concept]
- VP-BBML protocol [MeSH Supplementary Concept]
- VP-P protocol [MeSH Supplementary Concept]
- VPC regimen [MeSH Supplementary Concept]
- VPCBAE protocol [MeSH Supplementary Concept]
- VPQ compound [MeSH Supplementary Concept]
- VlhP protocol [MeSH Supplementary Concept]
- etoposide 4'-sulfate [MeSH Supplementary Concept]
- etoposide glucuronide [MeSH Supplementary Concept]
- etoposide phosphate [MeSH Supplementary Concept]
- stanford V protocol [MeSH Supplementary Concept]
- vvp protocol [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Etoposide [ICD-11 Extension code]
- Etoposide [NCIt concept]
- Etoposide (substance) [SNOMED CT concept]
- Product containing etoposide (medicinal product) [SNOMED CT concept]
- etoposide [ATC Code]
- etoposide [Substance BNPC]
- etoposide [SNOMED Notion]
Validated automatic mappings to BTNT
- etoposide [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients